Oncology Meeting Resources

International Congress on Targeted Anticancer Therapies 2012

08 Mar - 10 Mar, Amsterdam, Netherlands

From this page, you may download, if you are an ESMO member, a PDF version of presentations given at TAT 2012 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Search Meeting Resources by Keyword

 

Useful link

Presenter Presentation title Session title
Elizabeth Eisenhauer NDDO Honorary Award Lecture 2012: Miles to go before we sleep: Fifteen years of targeted therapy development and the path ahead Opening Ceremony
Antoine Hollebecque A phase 1 study of LY2584702, a p70S6 kinase inhibitor, with erlotinib or everolimus in patient with advanced solid tumours Phase I Studies, Completed or in Progress
Karim Benhadji A phase 1 dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of oral LY2584702 a p70S6 kinase inhibitor Phase I Studies, Completed or in Progress
Aled Edwards Genomics in drug discovery and development New Technologies and Models in Drug Discovery and Development
Amita Patnaik The evolution of PI3 kinase inhibitors: Results of a first-in-human Phase I study of BAY 80-6946 in patients with advanced solid tumours Phase I Studies, Completed or in Progress
Lee Ellis Keynote Lecture: Challenges in translating success from the lab to the clinic: A perspective on our current infrastructure and suggestions on ways to improve it Opening Ceremony
Alain Herrera NBTXR3 nanoparticles for radioenhancement: Rationale for the first- in-man study in advanced soft tissue sarcoma New Technologies and Models in Drug Discovery and Development
Marie-Catherine Vozenin New drugs on the horizon targeting stem cells in NSCLC Stem Cells and Cancer Stem Cells
Josep Tabernero PI3K pathway inhibitors: How deep should we go? Phase I Studies, Completed or in Progress
Jean Charles Soria First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumours Phase I Studies, Completed or in Progress
Roger Griffin Educational introduction: DNA repair inhibitors; a medicinal chemist's perspective DNA Repair Beyond PARP
Ruth Plummer Understanding failure of PARP inhibition in the clinic DNA Repair Beyond PARP
Shivani Kummar Development of markers of DNA repair DNA Repair Beyond PARP
John Pollard Inhibition of the DNA damage response kinase, ATR, as a promising anti-cancer approach DNA Repair Beyond PARP
Ahmad Awada Educational introduction: How to optimise strategies for clinical development of combinations based on targeted Agents Combining Targeted Agents